Latest Industry Insights

While oncolytic virus (OV) therapy has garnered increasing attention from the cancer research community, this therapeutic strategy doesn’t come without its challenges, as a patient’s immune system can sometimes mount a response to the OVs before they reach their intended target. To address this, Calidi Biotherapeutics has developed cell-based platforms to shield OVs from the immune system, so that they can effectively target and destroy the cancer cells.

Technology Networks had the pleasure of interviewing Sunny Himansu M.B.B.S., D.SM – associate director, infectious diseases at Moderna – to discuss the biotech company's pipeline, how a collaboration with IAVI aims to make mRNA-based preventives and therapeutics globally accessible and the future of mRNA in medicine.

The intricate and intertwined nature of the host‒microbiota connection has garnered increasing interest from the scientific community in recent years, due to its known role in the development and progression of various diseases. 4D pharma has leveraged growing knowledge in the field, by creating a novel class of medicines called live biotherapeutic products (LBPs).

In this interview we speak to Sean Mackay, CEO of IsoPlexis, to discuss how single-cell functional proteomics have helped researchers understand the risk factors behind long COVID.

Emulate's chief scientific officer, Dr. Lorna Ewart, talks about inspiring a new generation of women in STEM.

Technology Networks spoke to Dr. Tomas Richardson from PBD Biotech, to hear more about how bacteriophage can be used to diagnose tuberculosis in both humans and cattle.

Technology Networks spoke to Atara’s chief medical officer, AJ Joshi, to learn more about ATA188 – an off-the-shelf, allogeneic T-cell immunotherapy – and how it could revolutionize treatment for MS patients.

Technology Networks recently spoke with Jakob Dupont, head of global research & development at Atara Bio, to learn more about the company’s novel allogeneic EBV T-cell platform and discover how it’s enabling a differentiated approach to allogeneic cell therapy.

In honor of International Day of Women and Girls in Science 2022, Technology Networks interviewed three women who have built successful careers within the scientific industry, to learn about their career paths and the reasons they chose to work in industry.

In this interview, we speak to Dr. Antal Szalay, CEO of Ultimate Medicine, about how his company helped establish that a microbiome metabolite can cause age-related memory loss.